{"schema_version":"secwatch.filing_event.v1","accession":"0001438133-25-000091","form_type":"8-K","ticker":"TNDM","cik":"0001438133","company_name":"TANDEM DIABETES CARE INC","filed_at":"2025-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.300843+00:00","generated_at":"2026-05-20T23:52:15.008555+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tandem Diabetes receives CE mark approval for Tandem Mobi with Control-IQ+; EU launch planned by end 2025","bullets":["CE mark granted for Tandem Mobi insulin delivery system with Control-IQ+ technology.","Company will pursue in-country registrations and reimbursement in EU markets.","EU commercial launches targeted to begin by end of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001438133-25-000091","json":"https://secwatch.observer/filing/0001438133-25-000091.json","markdown":"https://secwatch.observer/filing/0001438133-25-000091.md","text":"https://secwatch.observer/filing/0001438133-25-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000091/0001438133-25-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1438133/000143813325000091/tndm-20250516.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T23:52:15.008555+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}